Nepafenac dosing frequency for @entity3856 and @entity32 associated with XXXX surgery.

@entity1 @entity32 @entity231 @entity5353 @entity158 @entity3856
PURPOSE: Nepafenac ophthalmic suspension 0.1% was dosed topically once (QD), twice ( @entity5353 ), or three-times (TID) daily to assess the resolution of @entity3856 and anterior-segment @entity32 following @entity231 surgery. METHODS: This was a prospective, multicenter, double-masked, randomized, placebo-controlled study of 212 adults. @entity1 received nepafenac 0.1% or placebo, 1 drop QD, @entity5353 , or TID beginning 1 day before @entity231 surgery, continuing on the day of surgery, and for 14 days thereafter. One (1) additional drop was administered 30-120 min prior to surgery. The primary efficacy endpoint was percent of treatment failures (>or=16 aqueous cells, aqueous flare = severe, or @entity3856 score = moderately severe or severe) through postoperative day 14. RESULTS: On days 7 and 14, the QD, @entity5353 , and TID all nepafenac posologies significantly reduced the percent of treatment failures, compared to placebo ( p <or= 0.0029). Compared with placebo, the TID posology achieved statistical significance beginning on day 3 ( p <or= 0.0080). Nepafenac treatment significantly increased the proportion of @entity1 with @entity32 , compared to placebo, beginning on day 1 for TID dosing ( p <or= 0.0208) and beginning on day 3 for QD dosing ( p <or= 0.0483). A significantly greater percentage of nepafenac-treated @entity1 were @entity158 free, compared to placebo, beginning on postoperative day 1 with @entity5353 and TID dosing ( p <or= 0.0150) and beginning on day 3 for QD dosing (p <or= 0.0220). No serious ocular adverse events were reported, and fewer @entity1 experienced adverse events in the nepafenac groups than in the placebo group. CONCLUSIONS: Nepafenac ophthalmic suspension 0.1% was well tolerated and effectively @entity32 and increased the incidence of @entity3856 -free @entity1 following @entity231 surgery when dosed QD, @entity5353 , or TID. By postoperative day 14, all nepafenac posologies significantly reduced the incidence of treatment failures and the incidence of @entity1 presenting with @entity32 , and significantly increased the incidence of @entity3856 -free @entity1 relative to placebo.
